Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index.
Abstract
One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin were examined. Twenty-four Wistar albino rats were distributed in four different groups, and a high-fat diet and streptozotocin were used to induce type 2 in two groups. Rats in the untreated control groups were administered 0.9% NaCl solution over a 6-week period, and those in the treatment groups were administered 0.9% NaCl for 3 weeks, followed by subcutaneous injection of liraglutide (150 μg/kg) for an additional 3 weeks. In the liraglutide-treated diabetic group, the heart-to-body weight ratio was significantly reduced, levels of cardiac biomarkers, troponin I and creatine-kinase-MB, were improved; activities of antioxidant enzymes, glutathione peroxidase and superoxide dismutase, were increased; and levels of malondialdehyde were decreased. Western blotting and immunohistochemical studies revealed increased levels of ILK, P-PI3K, P-AKT, and BCL2, as well as those of caspase 3, BAX, and P-PTEN, indicating mitigation of cardiomyocyte apoptosis. Our results show that liraglutide, by targeting GLP1Rs, enhances the expression of proteins in the ILK/PI3K/AKT/PTEN pathway and thereby exerts its cardioprotective effects in rats with DCM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The anti-tumor effect of liraglutide is related to its inhibition of the PI3K/Akt signaling pathway, as the activation of Akt is crucial for promoting cell survival and proliferation, and liraglutide can inhibit this process in a dose-dependent manner.520,526”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [526]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385 · cited 1×
“Western blot analysis was performed using the technique described by Towbin et al. [75].”
MethodRaza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
Ohkawa, H., Ohishi, N., & Yagi, K. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90738-3 · Cited by 29,297 · cited 1×
“MDA levels were estimated with a thiobarbituric acid (TBA) assay according to the description of Ohkawa et al. [73].”
MethodSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“Individuals with T2DM have twice the risk of cardiovascular complications compared to their nondiabetic counterparts [4].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 3×
“These findings align with our results, corroborating the protective effect of liraglutide against DCM reported in a previous study [27].”
BackgroundResultInfluentialMORON, M., DEPIERRE, J., & MANNERVIK, B. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90289-7 · Cited by 4,208 · cited 1×
“In order to determine GPx activity, the method proposed by Moron et al. was used [72].”
MethodGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Hannigan, G. E., Leung-Hagesteijn, C., Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, J. C., & Dedhar, S. (1996) · Nature · doi:10.1038/379091a0 · Cited by 1,110
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Jia, G., DeMarco, V. G., & Sowers, J. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 949 · cited 2×
“…system is postulated to be a key mechanism in cardiac insulin resistance, which promotes insulin resistance via an increase in the phosphorylation of serine residues in insulin receptor substrate 1 (IRS1), leading to the impairment of PI3K engagement and AKT stimulation [6].”
BackgroundDiabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease
Jia, G., Whaley-Connell, A., & Sowers, J. R. (2018) · Diabetologia · doi:10.1007/s00125-017-4390-4 · Cited by 868
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 1×
“Three new targets for antidiabetic agents, glucagon-like peptide 1 receptor (GLP1R), dipeptidylpep-tidase 4 (DPP4), and sodium-glucose cotransporter 2 (SGLT2), have gained popularity because of their crucial role in DCM [20].”
BackgroundMargulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Bock-Marquette, I., Saxena, A., White, M. D., Michael DiMaio, J., & Srivastava, D. (2004) · Nature · doi:10.1038/nature03000 · Cited by 657 · cited 1×
“After myocardial infarction, activation of ILK promotes cardiac repair, suggesting a potential target for therapeutic interventions [16].”
BackgroundModeling type 2 diabetes in rats using high fat diet and streptozotocin
Skovsø, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12235 · Cited by 596 · cited 2×
“…strategies DCM, an unfavorable condition resulting from type 2 diabetes [31], was modeled in this study using the STZ/high-fat diet (HFD) model [32]. with potential clinical applications in diverse cardiovascular diseases, particularly DCM. DCM, an unfavorable condition resulting from type…”
MethodPTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M.-M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 482 · cited 1×
“This underscores the significance of ILK not only as a kinase that influences PI3K/AKT but also as a regulator of PTEN, affirming the role of PTEN as a negative regulator of PI3K and ILK overexpression [12,55].”
BackgroundGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · cited 1×
“Real-time quantitative polymerase chain reaction and in situ hybridization studies have detected GLP1R mRNA transcripts and the GLP-1R immunoreactive protein within cardiomyocytes of human tissue [57].”
BackgroundDiabetes Mellitus and Cause-Specific Mortality: A Population-Based Study
Li, S., Wang, J., Zhang, B., Li, X., & Liu, Y. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0060 · Cited by 290 · cited 1×
“One of the features of diabetes mellitus is that the levels of blood glucose are raised as a result of a decline in the secretion or activity of insulin, which is a significant global health concern [1].”
BackgroundApoptosis in ischemic heart disease
Teringova, E., & Tousek, P. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1191-y · Cited by 272 · cited 2×
“…contribution of antiapoptotic effects to its cardioprotective action against DCM. Apoptosis, a pivotal factor in DCM and a manifestation of ischemic myocardial injury [45,46], is more pronounced in diabetic rats than in nondiabetic rats during ischemia/ reperfusion-induced apoptotic injuries.”
BackgroundNakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073587 · Cited by 268 · cited 2×
“…GLP1R is pivotal for identifying novel therapeutic targets and for devising strategies DCM, an unfavorable condition resulting from type 2 diabetes [31], was modeled in this study using the STZ/high-fat diet (HFD) model [32]. with potential clinical applications in diverse cardiovascular diseases,…”
MethodRecent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265 · cited 1×
“Among these targets, GLP1Rs are expected to become the preferred drug targets for diabetes and its associated cardiac complications in the future, surpassing current options owing to their specificity, lower toxicity, and ability to overcome drawbacks, such as weight gain and hypoglycemia [21].”
BackgroundDavies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235 · cited 2×
“The LEADER trial highlighted lower rates of cardiovascular death in patients with T2DM on liraglutide [26].”
BackgroundOxidative Stress in Pancreatic Beta Cell Regeneration
Wang, J., & Wang, H. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1930261 · Cited by 233 · cited 1×
“Oxidative stress has been implicated in functional injury to islet β cells and peripheral insulin resistance, contributing to the onset of diabetes and its severe complications, including cardiovascular diseases [43,44].”
BackgroundDiabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage
Liu, Q., Wang, S., & Cai, L. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12250 · Cited by 206 · cited 1×
“Diabetic complications are complex and prominent diseases, and multiple pathological mechanisms, including oxidative stress [36], apoptosis, inflammation, and mitochondrial dysfunction [66], are linked.”
BackgroundWhite, D. E., Coutu, P., Shi, Y.-F., Tardif, J.-C., Nattel, S., St. Arnaud, R., Dedhar, S., & Muller, W. J. (2006) · Genes & Development · doi:10.1101/gad.1458906 · Cited by 166 · cited 1×
“Targeted ILK deletion in the murine heart has been linked to dilated cardiomyopathy and spontaneous heart failure [19].”
BackgroundIntegrin-Linked Kinase at the Heart of Cardiac Contractility, Repair, and Disease
Hannigan, G. E., Coles, J. G., & Dedhar, S. (2007) · Circulation Research · doi:10.1161/01.res.0000265233.40455.62 · Cited by 163 · cited 2×
“Its expression is the highest in the heart, and alterations in its activity can lead to cardiomyopathy or sudden death [15].”
BackgroundZhang, S., Xu, H., Yu, X., Wu, Y., & Sui, D. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4475 · Cited by 160 · cited 1×
“To induce type 2 diabetes in rats, STZ (30 mg/kg) was injected intraperitoneally once after 24 h fasting and was aided by feeding an HFD [68,69].”
MethodDiabetic cardiomyopathy: prevalence, determinants and potential treatments
Gulsin, G. S., Athithan, L., & McCann, G. P. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819834869 · Cited by 157
Suzuki, H., Kayama, Y., Sakamoto, M., Iuchi, H., Shimizu, I., Yoshino, T., Katoh, D., Nagoshi, T., Tojo, K., Minamino, T., et al. (2014) · Diabetes · doi:10.2337/db13-1896 · Cited by 141 · cited 1×
“Oxidative stress has been implicated in functional injury to islet β cells and peripheral insulin resistance, contributing to the onset of diabetes and its severe complications, including cardiovascular diseases [43,44].”
BackgroundLiu, Q., Anderson, C. M., Broyde, A., Polizzi, C. J., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 133
The benefits of GLP1 receptors in cardiovascular diseases
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1293926 · Cited by 127 · cited 1×
“Previous reports have indicated that GLP-1 receptors are expressed within cardiomyocytes [56].”
Vinayagam, R., & Saravanan, R. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327114561663 · Cited by 121
Walkowski, B., Kleibert, M., Majka, M., & Wojciechowska, M. (2022) · Cells · doi:10.3390/cells11091553 · Cited by 117 · cited 2×
“Extensive evidence supports the role of insulin in promoting cell survival through PI3K/AKT activation [10].”
BackgroundZheng, C., Hu, H., Hong, P., Zhang, Q., Xu, W., He, Q., & Li, B. (2019) · Europe PMC (PubMed Central) · Cited by 95
Wang, H. J., Jin, Y., Shen, W., Neng, J., Wu, T., Li, Y. J., & Fu, Z. (2007) · PubMed · Cited by 92
Wu, M., Zhang, Y., Zhou, Q., Xiong, J., Yao-rong, D., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.032 · Cited by 87
Urschel, K., Tauchi, M., Achenbach, S. S., & Dietel, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115635 · Cited by 86 · cited 1×
“Chronic hyperglycemia is implicated in direct impairment of the PI3K/AKT signaling pathway, which is a pivotal step in insulin action [51].”
BackgroundBułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., & Okopień, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.008 · Cited by 84 · cited 1×
“The pharmacological targeting of GLP-1 receptors has been shown to reduce inflammatory responses via the Akt protein kinase pathway [62].”
BackgroundYang, Y., Fang, H., Xu, G., Zhen, Y., Zhang, Y., Tian, J., Zhang, D., Zhang, G., & Xu, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9180 · Cited by 84 · cited 1×
“…authors also investigated the molecular mechanism underlying liraglutide’s neuroprotective effect and reported that it increased the expression of the mammalian target of rapamycin (mTOR) in hippocampus tissue in diabetic rats via the AMP-activated protein kinase (AMPK) and PI3K/AKT pathways [29].”
BackgroundMcLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82
Cai, C., Wu, F., He, J., Zhang, Y., Shi, N., Peng, X., Ou, Q., Li, Z., Jiang, X., Zhong, J., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75402 · Cited by 81 · cited 1×
“Diabetic complications are complex and prominent diseases, and multiple pathological mechanisms, including oxidative stress [36], apoptosis, inflammation, and mitochondrial dysfunction [66], are linked.”
BackgroundLeft Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
Mohan, M., Dihoum, A., Mordi, I. R., Choy, A. M., Rena, G., & Lang, C. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.746382 · Cited by 77 · cited 1×
“This model is renowned for inducing The early stages of DCM manifest various pathological changes, including left ventricular hypertrophy, cardiac fi brosis, in fl am-mation, and oxidative stress [35–37].”
BackgroundAlmutairi, M., Gopal, K., Greenwell, A. A., Young, A., Gill, R., Aburasayn, H., Al Batran, R., Chahade, J. J., Gandhi, M., Eaton, F., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.098 · Cited by 72 · cited 1×
“Several animal studies have shown that liraglutide can attenuate systolic and diastolic dysfunction in rodents with type 2 diabetes [23,24].”
BackgroundRotkvić, P. G., Planinić, Z., Pršo, A.-M. L., Šikić, J., Galić, E., & Rotkvić, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115973 · Cited by 66 · cited 1×
“This model is renowned for inducing The early stages of DCM manifest various pathological changes, including left ventricular hypertrophy, cardiac fi brosis, in fl am-mation, and oxidative stress [35–37].”
BackgroundSu, Y., Lee, W.-C., Wang, C.-C., Yeh, S., Chen, W., & Chen, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415749 · Cited by 66
PI3K kinase and scaffold functions in heart
Damilano, F., Perino, A., & Hirsch, E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05081.x · Cited by 59 · cited 1×
“The serine/threonine protein kinase, ILK, is bound to β -integrins’ cytoplasmic tail, thus establishing a connection between cell–matrix interactions and signals responsible for regulating different processes in the cell [14].”
BackgroundTrang, N. N., Chung, C., Lee, T., Cheng, W., Kao, Y., Huang, S.-Y., Lee, T.-I., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031177 · Cited by 59 · cited 3×
“Furthermore, the pharmacological modulation of phosphoinositide 3-kinase (PI3K) by liraglutide has been supported previously [60].”
BackgroundResultInfluentialZhang, C., Zhang, L., Chen, S., Feng, B., Lu, X., Bai, Y., Liang, G., Tan, Y., Shao, M., Skibba, M. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082287 · Cited by 54 · cited 2×
“…contribution of antiapoptotic effects to its cardioprotective action against DCM. Apoptosis, a pivotal factor in DCM and a manifestation of ischemic myocardial injury [45,46], is more pronounced in diabetic rats than in nondiabetic rats during ischemia/ reperfusion-induced apoptotic injuries.”
BackgroundGodoy-Parejo, C., Deng, C., Liu, W., & Chen, G. (2019) · Stem Cells · doi:10.1002/stem.3026 · Cited by 54 · cited 1×
“The PI3K/AKT signaling pathway, known for its effects on cardiomyocyte survival and function, is activated by insulin, thereby promoting cell survival [10,52].”
BackgroundKitamura, Y., Koide, M., Akakabe, Y., Matsuo, K., Shimoda, Y., Soma, Y., Ogata, T., Ueyama, T., Matoba, S., Yamada, H., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.508143 · Cited by 53 · cited 1×
“Cardiac-specific knockout of PTEN protected the heart from cardiac dysfunction, probably through the upregulation of ILK and AKT [11–13].”
BackgroundYu, W., Zha, W., Guo, S., Cheng, H., Wu, J., & Liu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098044 · Cited by 49 · cited 1×
“Myocardial cell injury due to apoptosis has been identified as a significant cause of various heart diseases [45,47].”
BackgroundLiu, J., Liu, Y., Chen, L., Wang, Y., & Li, J. (2013) · Journal of Diabetes Research · doi:10.1155/2013/630537 · Cited by 48 · cited 1×
“It is pertinent to mention that ER is a critical factor in the intrinsic apoptosis pathway [50].”
BackgroundObara, S., Nakata, M., Takeshima, H., Katagiri, H., Asano, T., Oka, Y., Maruyama, I., & Kuratsu, J. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.11.020 · Cited by 44 · cited 2×
“This underscores the significance of ILK not only as a kinase that influences PI3K/AKT but also as a regulator of PTEN, affirming the role of PTEN as a negative regulator of PI3K and ILK overexpression [12,55].”
BackgroundWu, H., Sheng, Z.-Q., Xie, J., Li, R., Chen, L., Li, G., Wang, L., & Xu, B. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9836860 · Cited by 44 · cited 1×
“Oxidative stress, a critical aspect in the process by which type 2 diabetes develops [42], manifests when there is a lack of balance between the generation and elimination of reactive oxygen species (ROS).”
BackgroundDelides, A., Spooner, R. J., Goldberg, D. M., & Neal, F. E. (1976) · Journal of Clinical Pathology · doi:10.1136/jcp.29.1.73 · Cited by 40 · cited 1×
“The nitro blue tetrazolium technique was used to determine the SOD activity, as described by Delides et al. [74].”
MethodLarsen, P. J., Wulff, E. M., Gotfredsen, C. F., Brand, C. L., Sturis, J., Vrang, N., Knudsen, L. B., & Lykkegaard, K. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00865.x · Cited by 40 · cited 1×
“Both the heart weight-to-body weight ratio and fasting blood glucose levels were improved in rats when they were treated with liraglutide, thus mitigating cardiovascular risk factors [38].”
BackgroundFarrag, E. A. E., Hammad, M. O., Safwat, S. M., Hamed, S. M., & Hellal, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-37678-w · Cited by 39 · cited 1×
“Blood glucose levels > 200 mg/dL in two consecutive assessments indicated diabetes in rats [70].”
BackgroundApplication of Animal Models in Diabetic Cardiomyopathy
Lee, W. S., & Kim, J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0285 · Cited by 38 · cited 1×
“…to type 2 diabetes, including insulin resistance, which a ff ects glucose uptake by cardiac cells and disrupts energy metabolism, thereby leading to cardiac anomalies resembling diabetic cardiomyopathy [33,34]. diabetes [31], was modeled in this study using the STZ/high-fat diet (HFD) model [32].”
MethodLiraglutide protects cardiac function in diabetic rats through the PPARα pathway
Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., Wang, T., & Wang, X. (2018) · Bioscience Reports · doi:10.1042/bsr20180059 · Cited by 36 · cited 1×
“Furthermore, liraglutide has been reported to ameliorate left ventricular dysfunction and reduce the heart rate in diabetic rats [25].”
BackgroundPeripheral insulin resistance in ILK-depleted mice by reduction of GLUT4 expression
Hatem-Vaquero, M., Griera, M., García‐Jérez, A., Luengo, A., Álvarez, J., Rubio, J. A., Calleros, L., Rodríguez-Puyol, D., Rodríguez-Puyol, M., & de Frutos, S. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0662 · Cited by 34 · cited 2×
“Interestingly, cardiac ILK depletion in mice reportedly promotes insulin resistance by increasing the phosphorylation of insulin receptors and decreasing the phosphorylation of AKT in conjunction with decreased GLUT4 transcription [53].”
BackgroundChu, D., & Zhang, Z. (2018) · Molecules · doi:10.3390/molecules23102409 · Cited by 33 · cited 1×
“Specifically, AKT exhibits a cytoprotective function through the activation of downstream effector molecules, including the antiapoptotic BCL2 [46,49].”
BackgroundElekofehinti, O. O., Oyedokun, V. O., Iwaloye, O., Lawal, A. O., & Ejelonu, O. C. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00739-w · Cited by 30 · cited 2×
“Also, the molecular modulation of P13K/Akt/PTEN signaling in the streptozotocin-induced diabetic model is already established [63].”
BackgroundZhang, Z., Wang, X., Yang, L., Yang, L., & Ma, H. (2021) · PubMed Central · doi:10.22038/ijbms.2021.56771.12677 · Cited by 30 · cited 1×
“A significant reduction in the heart weight-to-body weight ratio observed in rats with diabetes that received liraglutide treatment—a pattern commonly observed in preclinical studies and clinical trials—further supports the cardioprotective effects of liraglutide [39–41].”
ResultAndonova, M., Dzhelebov, P., Trifonova, K., Yonkova, P., Kostadinov, N. N., Nancheva, K., Иванов, В., Gospodinova, K., Nizamov, N., Tsachev, I., et al. (2023) · Veterinary Sciences · doi:10.3390/vetsci10070431 · Cited by 30 · cited 1×
“…to type 2 diabetes, including insulin resistance, which a ff ects glucose uptake by cardiac cells and disrupts energy metabolism, thereby leading to cardiac anomalies resembling diabetic cardiomyopathy [33,34]. diabetes [31], was modeled in this study using the STZ/high-fat diet (HFD) model [32].”
MethodLi, L., Su, Q., Wang, Y., Dai, R., Lu, Y., Su, B., & Zhao, Y. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9199-z · Cited by 27 · cited 1×
“This value was multiplied by 100 [76].”
Wu, X.-M., Ou, Q., Zhao, W., Liu, J., & Zhang, H.-L. (2014) · Experimental and clinical endocrinology & diabetes · doi:10.1055/s-0034-1384584 · Cited by 25 · cited 1×
“…vitro study using H9c2 cells demonstrated that GLP-1R agonists protected cardiomyocytes against apoptosis (measured using TUNEL assay), and the protective effect attenuated by PI3K and/or extracellular signal-regulated kinase 1/2 (ERK1/2) inhibition was confirmed via an immunoblotting assay [30].”
MethodBajić, Z., Šobot, T., Uletilović, S., Mandić-Kovačević, N., Cvjetković, T., Maličević, U., Đukanović, Đ., Duran, M., Vesić, N., Avram, S., et al. (2023) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0534 · Cited by 21 · cited 1×
“A significant reduction in the heart weight-to-body weight ratio observed in rats with diabetes that received liraglutide treatment—a pattern commonly observed in preclinical studies and clinical trials—further supports the cardioprotective effects of liraglutide [39–41].”
ResultTj, X., Liu, Y., & Yuan, B. (2011) · PubMed · Cited by 15
Madhu, D., Hammad, M. M., Kavalakatt, S., Khadir, A., & Tiss, A. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201600169 · Cited by 9 · cited 1×
“It was reported that the pharmacological application of a GLP-1 agonist modulates the ILK in human HepG2 cells [64].”
BackgroundImpact of liraglutide on microcirculation in experimental diabetic cardiomyopathy
Soliman, N. G. A., Abdel‐Hamid, A. A. M., El‐Hawwary, A. A., & EL-Lakany, A. S. (2020) · Acta Histochemica · doi:10.1016/j.acthis.2020.151533 · Cited by 9 · cited 2×
“The dose was chosen based on previous studies demonstrating its cardioprotective effects in diabetic rats [71].”
MethodBernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9 · cited 1×
“GLP1 agonists, including liraglutide, exhibit significant cardiovascular benefits and have been approved for diabetes treatment [22].”
BackgroundDiabetic Endothelial Cell Glycogen Synthase Kinase 3β Activation Induces VCAM1 Ectodomain Shedding
Brishti, M. A., Raghavan, S., Lamar, K., Singh, U. P., Collier, D. M., & Leo, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814105 · Cited by 9 · cited 1×
“ILK activity can be stimulated by growth factor stimulation and matrix attachment in a PI3K-dependent manner [17], as well as by PKB/AKT phosphorylation [18].”
BackgroundDayel, A. F. B., Alonazi, A. S., Al‐Rasheed, N. M., Alamin, M. A., Sarawi, W. S., Alharbi, A. O., Alabbad, N. A., Albuaijan, D. A., Alassiri, D., Aljarbua, A. F., et al. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad111 · Cited by 9
Self-citationAntitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s392051 · Cited by 6 · cited 1×
“The modulation of PI3K/Akt/PTEN by liraglutide has been examined previously but in the context of hepatocellular carcinoma [67].”
BackgroundWang, L., Tang, Y., He, H., & Wei, W. (2021) · Acta Cirúrgica Brasileira · doi:10.1590/acb360207 · Cited by 4 · cited 1×
“Accumulating evidence has shown that targeting GLP-1 signaling is an effective approach to improving cardiovascular outcomes in preclinical models of diabetes [61].”
BackgroundCanu, M., Carabelli, A., Debiossat, M., Broisat, A., Desvignes, M., Ghezzi, C., Barone‐Rochette, G., & Riou, L. M. (2020) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/j.acvdsp.2020.03.034 · Cited by 2 · cited 1×
“Several animal studies have shown that liraglutide can attenuate systolic and diastolic dysfunction in rodents with type 2 diabetes [23,24].”
BackgroundTrefts, E. (2019) · Cited by 1
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“520,526 In the context of T2DM, liraglutide, by regulating the PI3K/Akt pathway and activating GLP-1R, effectively inhibits the growth and spread of pancreatic cancer cells.”
BackgroundCurrent Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“Liraglutide targets pathways such as the GLP-1 receptor pathway, insulin signaling (IRS-1/2, PI3K, and AKT), AMPK, and NF-κ B, resulting in enhanced fatty acid oxidation, reduced lipogenesis, and decreased hepatic inflammation [325].”
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“In addition to vascular protective effects, GLP-1R agonism improves experimental heart failure across several species, including mice (21–32), rats (33–37), pigs (38, 39), and dogs (40, 41) (Figure 2).”
Bajić, Z., Šobot, T., Amidžić, L., Vojinović, N., Jovičić, S., Bojić, M. G., Djuric, D. M., Stojiljković, M. P., Bolevich, S., & Škrbić, R. (2024) · Biomedicines · doi:10.3390/biomedicines12061207 · Cited by 12
“On the other hand, some findings suggest that liraglutide, through Akt, inhibits NF-κ B, decreases BAX and caspase-3, and increases BCL-2 in diabetic cardiomyopathy [55,56].”
BackgroundResearch Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy
Yang, X., & Li, X. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm37180 · Cited by 6
“[67] 24 Wistar albino rats The rats were divided into four groups, with T2DM induced using a high-fat diet and STZ.”
Influential
Metadata
- Authors
- Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., Almasud, D. H., Al-Ammar, S. E., Almadhi, S. O., Almalke, R. A., Aldamri, N. T., Alghibiwi, H. K., Alkhelb, D. A., & Alrasheed, N. M.
- Affiliations
- King Saud University (SA)
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
- Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-03-15
- Volume
- 17
- Issue
- 3
- Pages
- 374
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC10975938
- OpenAlex
- W4392858803
- Cited by
- 13
- References
- 80
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 3
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Education in Saudi Arabia (IFKSUDR_H150)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, diabetic cardiomyopathy, type 2 diabetes, integrin-linked kinase, PI3K/Akt signaling, PTEN, GLP-1 receptor agonists, streptozotocin-induced diabetes, cardiomyocyte apoptosis, oxidative stress, cardioprotection, Bcl-2, caspase-3, Bax
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.